T-Cell Therapy Approved for Aggressive Melanoma
April 30, 2024 | Terry Sharrer
“The Food and Drug Administration (FDA) has granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics, San Carlos, CA), a tumor-derived autologous T cell immunotherapy, for adult patients with unresectable or metastatic melanoma. It is the first, and the only one-time, T cell therapy to receive FDA approval for a solid tumor cancer. The application was granted Priority Review, Fast Track designation, Regenerative Medicine Advanced Therapy designation, and Orphan Drug designation.” MORE
Image Credit: InsidePrecisionMedicine